- Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drugRoyalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.Fierce Biotech · 2d ago↗ source
- As Maui recovers from devastating fires, a study offers vision for new rural health modelA study of the long-term health impact of the Lahaina wildfires is inspiring a new model for disaster recovery and support.STAT · 2d ago↗ source
- Opinion: STAT+: Hospitals’ AI may be drifting. Who’s watching?Senior leaders must treat AI governance as their own daily job, not something the technology committee handles quarterly, write Peter Pronovost, Justin Norden, and Kedar Mate.